KUALA LUMPUR, June 20 (Bernama) -- The National Blood Centre (PDN) registered a total of 180,651 blood donors last year as compared to 180,052 in the previous year, said its director Dr Noryati Abu Amin.
She said there were 82,619 new donors last year as compared to 76,213 recorded in 2016 and this was seen as positive sign in meeting the needs of patients at all hospitals under the Ministry of Health.
"In Malaysia, O is the most common blood type, followed by A and B and the rarest being AB blood type.
"At PDN there are two ways of donating blood. One method is whole blood donation which can be carried out every three months and the other is apherisis donation through an appointment system," she told Bernama here recently.
Dr Noryati said that apherisis donation was to donate specific blood components namely plasma, platelets or both, and once the components have been isolated the rest of the blood would be returned to the donor's body.
Dr Noryati added that on the average hospitals across the country need about 2,000 units of blood per day and the demand from hospitals in the Klang Valley alone, was about 500 units a day.
However she said, ahead of the festive season and school holidays, blood supply at hospitals nationwide would drop to below the safe limit of 3,000 blood bags a day.
"PDN will ensure that blood supply is always sufficient during the festive seasons by intensifying blood donation campaigns at locations such as shopping complexes and mosques.
"In addition, PDN will continue to work with blood campaign organisers, among them Mara Junior Science College Alumni (Ansara), non-governmental organisations, Prasarana Malaysia Berhad and Mass Rapid Transit Corporation (MRT Corp) Sdn Bhd," she added.
Dr Noryati added that demand for blood had escalated due to increase in the number of patients, development of medical technology and availability of specialty services at hospitals nationwide.
“As such, we encourage the public to come forward to donate blood at the PDN at Jalan Tun Razak, here or at any government hospital in the country, to ensure sufficient blood supply at all times,” she said.
By Durratul Ain Ahmad Fuad
KUALA LUMPUR (Bernama) – A potentially effective treatment for patients with relapsed and refractory acute lymphoblastic leukaemia (ALL) is in the works.
ALL is a type of blood cancer in which the bone marrow makes too many lymphocytes, a type of white blood cell.
Universiti Kebangsaan Malaysia’s teaching facility Hospital Canselor Tuanku Muhriz (HCTM) is collaborating with Plutonet Sdn Bhd on a study and clinical trial involving the Chimeric Antigen Receptor-T Cell (CAR-T) therapy, a revolutionary treatment found to be effective for ALL patients who cannot be treated with chemotherapy or are immune to it.read more ››
UMSC: Pain Management